In a significant leap forward for the pharmaceutical landscape, Scilex Holding Company (Nasdaq: SCLX) has announced two key developments that underline its commitment to innovative pain management solutions. Recently, the company revealed that it has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP), a prestigious recognition that confirms Scilex’s adherence to the highest standards in drug distribution. This accreditation comes on the heels of the company’s successful launch of GLOPERBA an FDA-approved SCLX Through these developments, Scilex fortifies its position as a leader in the non-opioid pain management space.
Recognition from NABP’
On September 12, 2024, Scilex Holding Company announced its achievement of the Drug Distributor Accreditation from the NABP. This vital certification is only granted to companies that meet comprehensive criteria established to ensure high standards of integrity and safety in drug distribution. This accreditation empowers Scilex to operate with enhanced credibility, allowing both healthcare providers and consumers to have confidence in the sourcing and quality of its products.
Scilex’s commitment to meeting NABP’s stringent standards is a reflection of its larger mission: to provide innovative, effective, and non-opioid solutions for patients suffering from acute and chronic pain. By satisfying all drug distributor criteria set by the NABP, Scilex demonstrates its commitment to operating ethically and transparently in a market that increasingly values accountability and quality.
Launch and Distribution of GLOPERBA’
In alignment with its mission, Scilex made
Comments